Skip to main content

Corticostriatal covariance patterns of 6–[18F]fluoro–L–dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease

Journal of Neurology volume 253, pages 340–348 (2006)Cite this article

Abstract

6–[18F]fluoro–L–dopa (FDOPA) is a common presynaptic dopaminergic tracer used in examinations by positron emission tomography (PET) for patients with Parkinson's disease (PD). The distinct metabolic covariance pattern in the uptake of [18F]fluorodeoxyglucose (FDG) can also be used to investigate PD pathology. Although the two tracers are widely used in PD research and clinical assessment, no thorough comparative studies of the tracers have been made. In this study, 25 PD patients were examined with FDOPA and FDG to investigate relationships and clinical correlates of metabolic and monoaminergic function in the Parkinsonian brain. A VOI (volume–of–interest) analysis was achieved by 3D spatial normalisation and fixed VOI–sets. The hemisphere ipsi– and contralateral to the predominant symptoms of PD was identified in each data set, and data across subjects were related using that laterality, rather than body side. Regional covariance patterns for FDOPA and FDG were derived from principal component analysis (PCA). The results demonstrated hemispheric asymmetries and sex–differences in the striatal FDOPA uptake, which were not seen with FDG. In addition, the PCA analysis identified a positive relationship between a major component in FDOPA uptake (associated with the striatal uptake) and an FDG component, which had positive loadings in the thalamus and the cerebellum. The subject scores for these components correlated positively, and both had a negative association with the clinical severity of the disease. The specific extrastriatal FDG covariance pattern contained the thalamus and the cerebellum, components of the previously reported PD related pattern, but not the striatum. The network correlated with both the severity of clinical symptoms of PD and the severity of nigrostriatal dopaminergic hypofunction. The results indicate that FDG PET, when combined with multivariate network analysis at group–level, can be used as an indicator of PD severity.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Antonini A, Vontobel P, Psylla M, Günther I, Maguire RP, Missimer J, Leenders KL (1995) Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 52:1183–1190

    CAS  PubMed  Google Scholar 

  2. Ashburner J, Friston KJ (1999) Nonlinear spatial normalisation using basis functions. Hum Brain Map 7:254–266

    Article  CAS  Google Scholar 

  3. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RS (1990) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113:1539–1552

    PubMed  Google Scholar 

  4. Cumming P, Boyes BE, Martin WRW, Adam M, Grierson J, Ruth T, McGeer EG (1987) The metabolism of [18F]6– fluoro–L–3. 4–dihydroxyphenylalanine in the hooded rat. J Neurochem 48:601–608

    CAS  PubMed  Google Scholar 

  5. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, Margouleff C, Eidelberg D (2002) Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 43:1324–1330

    PubMed  Google Scholar 

  6. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA (1990) The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5:203–213

    Article  CAS  PubMed  Google Scholar 

  7. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, Fahn S (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783–800

    CAS  PubMed  Google Scholar 

  8. Fahn S, Elton RL, the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Healthcare Information, pp 153–163

  9. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES (1987) Cerebral metabolism of 6–[18F]fluoro–L–3. 4–dihydroxyphenylalanine in the primate. J Neurochem 48:1077–1082

    CAS  PubMed  Google Scholar 

  10. Friston K, Holmes AP, Worsley KJ, Poline J–B, Frith CD, Frackowiak R (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Map 2:189–210

    Google Scholar 

  11. Garnett ES, Nahmias C, Firnau G (1984) Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 11:174–179

    CAS  PubMed  Google Scholar 

  12. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD (2002) Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord 17:782–788

    Article  PubMed  Google Scholar 

  13. Hoshi H, Kuwabara H, Leger G, Cumming P, Guttman M, Gjedde A (1993) 6–[18F]fluoro–L–dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13:57–69

    CAS  PubMed  Google Scholar 

  14. Hu MT, Chaudhuri KR, Jarosz J, Yaguez L, Brooks DJ (2002) An imaging study of parkinsonism among African– Caribbean and Indian London communities. Mov Disord 17:1321–1328

    Article  PubMed  Google Scholar 

  15. Johnson RA, Wichern DW (1998) Applied multivariate statistical analysis. Upper Saddle River: Prentice Hall

    Google Scholar 

  16. Kaasinen V, Någren K, Hietala J, Farde L, Rinne JO (2001a) Sex differences in extrastriatal dopamine D2–like receptors in the human brain. Am J Psychiatry 158:308–311

    Article  CAS  Google Scholar 

  17. Kaasinen V, Nurmi E, Brück A, Eskola O, Bergman J, Solin O, Rinne JO (2001b) Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124:1125–1130

    Article  CAS  Google Scholar 

  18. Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, Salokangas RK, Hietala J (2002) Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 52:759–763

    Article  CAS  PubMed  Google Scholar 

  19. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA (2000) Effect of age and gender on dopamine transporter imaging with [123I]FP–CIT SPET in healthy volunteers. Eur J Nucl Med 27:867–869

    CAS  PubMed  Google Scholar 

  20. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieris P, Antonini A, Missimer J, Leenders KL, Eidelberg D (1999) Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 40:1264–1269

    CAS  PubMed  Google Scholar 

  21. Moeller JR, Strother SC (1991) A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 11:A121–A135

    CAS  PubMed  Google Scholar 

  22. Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA (1987) Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 7:649–658

    CAS  PubMed  Google Scholar 

  23. Mozley LH, Gur RC, Mozley PD, Gur RE (2001) Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158:1492–1499

    Article  CAS  PubMed  Google Scholar 

  24. Oertel WH, Schwarz J, Leenders KL, Hundemer HP, Lledo A, Wolters EC on behalf of the Pelmopet–Study Group (2001) Results of a 3 year randomized, double–blind, PET–controlled study of Pergolide vs. L–dopa as Monotherapy in Early Parkinson's Disease (PELMOPET–trial). J Neurol Sci 187(Suppl 1):S444

    Google Scholar 

  25. Otsuka M, Kuwabara Y, Ichiya Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Kato M, Masuda K (1997) Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F–dopa and 18F–FDG. Ann Nucl Med 11:251–257

    CAS  PubMed  Google Scholar 

  26. Pohjalainen T, Rinne JO, Någren K, Syvälahti E, Hietala J (1998) Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 155:768–773

    CAS  PubMed  Google Scholar 

  27. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, Dagher A, Jenkins IH, Friston KJ, Brooks DJ (1999) Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa–PET study. Brain 122:1637–1650

    Article  PubMed  Google Scholar 

  28. Rottenberg DA, Moeller JR, Strother SC, Dhawan V, Sergi ML (1991) Effects of percent thresholding on the extraction of [18F]fluorodeoxyglucose positron emission tomographic region– of–interest data. J Cereb Blood Flow Metab 11:A83–A88

    CAS  PubMed  Google Scholar 

  29. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS (1990) Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 28:799–804

    Article  CAS  PubMed  Google Scholar 

  30. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H (1993) Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34:324–330

    CAS  PubMed  Google Scholar 

  31. Staley JK, Krishnan–Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, Maciejewski PK, O'Malley S, Innis RB (2001) Sex differences in [123I]beta–CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41:275–284

    Article  CAS  PubMed  Google Scholar 

  32. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J (1998) Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res 83:149–162

    CAS  PubMed  Google Scholar 

  33. Wienhard K (2002) Measurement of glucose consumption using [18F]fluorodeoxyglucose. Methods 27:218–225

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, University Hospital Groningen, 30001, 9700RB, Groningen, The Netherlands

    V. Kaasinen MD & K. L. Leenders

  2. Neuroimaging Centre, Behavioral and Cognitive Neurosciences, University of Groningen, 30001, 9700RB, Groningen, The Netherlands

    R. P. Maguire

  3. Lilly Deutschland GmbH, Saalburgstrasse 153, 61350, Bad Homburg, Germany

    H.–P. Hundemer

Authors
  1. V. Kaasinen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. P. Maguire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.–P. Hundemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. L. Leenders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Kaasinen MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kaasinen, V., Maguire, R.P., Hundemer, H. et al. Corticostriatal covariance patterns of 6–[18F]fluoro–L–dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease. J Neurol 253, 340–348 (2006). https://doi.org/10.1007/s00415-005-0993-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0993-7

Key words

  • Parkinson's disease
  • PET
  • FDG
  • FDOPA
  • PCA